PMID- 37426164
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 15
IP  - 6
DP  - 2023 Jun 30
TI  - Bacterial lysate add-on therapy in adult and childhood asthma: a systematic 
      review and meta-analysis.
PG  - 3143-3157
LID - 10.21037/jtd-22-1469 [doi]
AB  - BACKGROUND: It has been proposed that bacterial lysates may serve as a suitable 
      immunomodulatory oral medication to improve and control asthma symptoms. However, 
      the difference in its efficacy in adults and children remains unclear. METHODS: 
      Randomized controlled trials (RCTs) evaluating OM-85 add-on therapy in asthma 
      patients up to December 2021 were searched using PubMed, Scopus, Web of Science, 
      China National Knowledge Infrastructure (CNKI), Wanfang database, and WP (WeiPu) 
      database. Risk of bias was evaluated using the Cochrane risk of bias assessment 
      tool. RESULTS: A total of 36 studies were included. The results showed that OM-85 
      add-on treatment provided a 24% improvement in asthma symptom control [relative 
      rates (RR) =1.24, 95% confidence intervals (CI): 1.19-1.30], and also 
      significantly improved lung function, increased numbers of T-lymphocytes and the 
      subtypes, and elevated levels of interferon-gamma (IFN-gamma), interleukin-10 (IL-10), 
      and IL-12. Levels of serum immunoglobulin E (IgE), eosinophil cationic protein 
      (ECP) and pro-inflammatory cytokines (including IL-4 and IL-5) were suppressed in 
      the OM-85 add-on treatment group. Moreover, OM-85 add-on treatment showed more 
      prominent effects in asthmatic children than in asthmatic adults. CONCLUSIONS: 
      OM-85 add-on therapy showed important clinical benefits for patients with asthma, 
      especially asthmatic children. Further studies focusing on the immunomodulatory 
      function of OM-85 in personalized asthma treatment are warranted.
CI  - 2023 Journal of Thoracic Disease. All rights reserved.
FAU - Yao, Siyang
AU  - Yao S
AD  - Department of Allergy and Clinical Immunology, National Clinical Research Center 
      for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 
      Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
FAU - Qin, Rundong
AU  - Qin R
AD  - Department of Allergy and Clinical Immunology, National Clinical Research Center 
      for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 
      Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
FAU - Song, Xiaonan
AU  - Song X
AD  - Department of Allergy and Clinical Immunology, National Clinical Research Center 
      for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 
      Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
FAU - He, Li
AU  - He L
AD  - Department of Allergy and Clinical Immunology, National Clinical Research Center 
      for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 
      Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
FAU - Lin, Xinliu
AU  - Lin X
AD  - Department of Allergy and Clinical Immunology, National Clinical Research Center 
      for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 
      Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Allergy and Clinical Immunology, National Clinical Research Center 
      for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 
      Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou 
      Medical University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230529
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC10323573
OTO - NOTNLM
OT  - Asthma
OT  - bacterial lysates
OT  - clinical symptoms
OT  - immunotherapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-22-1469/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/07/10 06:42
MHDA- 2023/07/10 06:43
PMCR- 2023/06/30
CRDT- 2023/07/10 05:06
PHST- 2022/10/18 00:00 [received]
PHST- 2023/04/21 00:00 [accepted]
PHST- 2023/07/10 06:43 [medline]
PHST- 2023/07/10 06:42 [pubmed]
PHST- 2023/07/10 05:06 [entrez]
PHST- 2023/06/30 00:00 [pmc-release]
AID - jtd-15-06-3143 [pii]
AID - 10.21037/jtd-22-1469 [doi]
PST - ppublish
SO  - J Thorac Dis. 2023 Jun 30;15(6):3143-3157. doi: 10.21037/jtd-22-1469. Epub 2023 
      May 29.